After more than two years on the Food and Drug Administration’s shortage list, diabetes and weight loss drugs Ozempic and Wegovy are now considered available, The Hill reported Wednesday.
Although the drugs are still on the FDA’s shortage list, they’re no longer listed as “currently in shortage.” Denmark-based Novo Nordisk makes both medications, which contain semaglutide, a GLP-1 agonist.
A spokesperson for Novo Nordisk told The Hill, “This update is a result of our significant investment in capacity and ongoing communication with the FDA. Our intentional approach to gradually increase supply into the U.S. market is working.”
Read more at Newsmax© 2024 Newsmax. All rights reserved.